US EditionWegovy-maker Novo Nordisk to cut 9,000 jobs in restructuring
- Novo Nordisk announced on September 10, 2025, a company-wide restructuring to cut 9,000 jobs globally and simplify its organisation.
- The restructuring follows a profit warning, slowing US sales of Wegovy and Ozempic, and rising competition from Eli Lilly in obesity and diabetes markets.
- About 5,000 of the layoffs will occur in Denmark, representing roughly 11.5% of Novo Nordisk’s 78,400-strong workforce, reallocating resources to growth areas.
- The company expects annual savings of approximately 8 billion Danish crowns , with CEO Mike Doustdar stating, “Our company must evolve as well.”
- The overhaul aims to improve decision speed and prioritize investments, reflecting confidence despite lowering operating profit growth to 4-10% this year.
117 Articles
117 Articles
The Danish manufacturer of weight loss syringes has announced a comprehensive austerity program. It is due to the tough competition, favorable imitation medications and Donald Trump.
Faced with fierce competition in the market for anti-obesity medicines, particularly in the United States, the pharmaceutical lab announced this Wednesday a severe bleed in its workforce.
Novo Nordisk to cut 9,000 jobs and lowers profit forecast
Novo Nordisk will lay off 11 per cent of its global workforce and reduce its profit forecast for 2025, citing intensifying competition in the weight-loss drug market and slower growth. The Danish pharmaceutical group confirmed on Wednesday that 9,000 roles will be eliminated across 80 countries. Approximately 5,000 of those positions are in Denmark, where the company is headquartered. The workforce reduction is part of a restructuring plan aimed…
Ozempic maker to slash 9,000 jobs globally as competition intensifies
Novo Nordisk’s plans would result in around 11% of the pharmaceutical giant’s 78,400-strong workforce being axed. The maker of Ozempic and Wegovy has revealed plans to shed around 9,000 jobs globally as the company faces a fiercely competitive market for obesity drugs. Novo Nordisk’s plans would result in around 11% of the pharmaceutical giant’s 78,400-strong workforce being axed. The majority of the job cuts, around 5,000, are expected in its h…
Coverage Details
Bias Distribution
- 41% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
